Theralase Technologies (CVE:TLT) Trading 1.8% Higher – What’s Next?

Shares of Theralase Technologies Inc. (CVE:TLT) traded up 1.8% on Friday . The company traded as high as C$0.30 and last traded at C$0.29. 191,650 shares were traded during mid-day trading, a decline of 15% from the average session volume of 226,799 shares. The stock had previously closed at C$0.28.

Theralase Technologies Trading Up 1.8%

The business has a 50 day moving average of C$0.25 and a 200 day moving average of C$0.21. The firm has a market capitalization of C$75.50 million, a price-to-earnings ratio of -15.83 and a beta of -0.13. The company has a debt-to-equity ratio of 14.85, a current ratio of 1.91 and a quick ratio of 3.40.

About Theralase Technologies

Theralase Technologies Inc, a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions.